CN1907957A - 阿戈美拉汀的新晶形ⅳ、它的制备方法和包含它的药物组合物 - Google Patents

阿戈美拉汀的新晶形ⅳ、它的制备方法和包含它的药物组合物 Download PDF

Info

Publication number
CN1907957A
CN1907957A CNA2006101083948A CN200610108394A CN1907957A CN 1907957 A CN1907957 A CN 1907957A CN A2006101083948 A CNA2006101083948 A CN A2006101083948A CN 200610108394 A CN200610108394 A CN 200610108394A CN 1907957 A CN1907957 A CN 1907957A
Authority
CN
China
Prior art keywords
crystalline form
agomelatine
disorder
pharmaceutical composition
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2006101083948A
Other languages
English (en)
Other versions
CN100445264C (zh
Inventor
G·科克雷尔
J·里诺尔
J-C·苏维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Publication of CN1907957A publication Critical patent/CN1907957A/zh
Application granted granted Critical
Publication of CN100445264C publication Critical patent/CN100445264C/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

式(I)化合物的晶形IV以及含有它的药物，该晶形以其粉末X射线衍射图表征。

Description

阿戈美拉汀的新晶形IV、它的制备方法和包含它的药物组合物
技术领域
本发明涉及阿戈美拉汀或式(I)的N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺的新晶形IV：
Figure A20061010839400041
它的制备方法以及包含它的药物组合物。
背景技术
阿戈美拉汀，或N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺，具有有价值的药理性质。
它确实具有双重的特征，一方面，它是褪黑激素能***受体的激动剂，另一方面，它是5-HT2C受体的拮抗剂。这些性质使得它在中枢神经***中具有活性，更特别是在严重抑郁症(severe depression)、季节性情感障碍、睡眠紊乱、心血管疾病、消化***疾病、由时差导致的失眠和疲劳、食欲紊乱和肥胖症的治疗中有活性。
阿戈美拉汀、它的制备和它的治疗用途在欧洲专利说明书EP 0 447285中已有描述。
鉴于该化合物的药学价值，获得纯度优良、具有很确定晶形且重现性极好的该化合物是重要的，其结果是在制剂方面呈现出有价值的特性，并且足够稳定以使得它可长时间储存而没有对温度、光、湿度或氧气水平的特定要求。
专利说明书EP 0447285描述了阿戈美拉汀从7-甲氧基-1-四氢萘酮起始的八步制备。但是，该文件中没有具体说明以可重现方式获得呈现这些特性的阿戈美拉汀的条件。
发明内容
本申请人现已开发了新的合成方法，该方法可以以很确定的、重现性极好的晶形获得阿戈美拉汀，所述晶形在制剂方面尤其显示出有价值的特性。
更具体而言，本发明涉及式(I)化合物的晶形IV，其以下列的粉末X射线衍射图表征，使用西门子D5005衍射计(铜对阴极)进行测定，以晶面间距d、布拉格2θ角、强度和相对强度(以最强射线的百分数表示)表示：
  2θ角(°)实测值   d(_)实测值   强度(％)
  5.0410.1610.5115.2216.7517.4118.0318.8120.4821.6123.2724.0424.2724.7725.5727.0627.95   17.5248.7038.4095.8185.2885.0894.9154.7144.3334.1103.8193.6993.6653.5913.4813.2923.190   86892839601007137161126422413611
本发明还涉及式(I)化合物的晶形IV的制备方法，该方法的特征在于，于110℃加热阿戈美拉汀直至完全熔化，然后在50和70℃之间迅速冷却，并在70℃维持约5小时直至结晶。
获得这种晶形的优点是其允许制备具有一致且可重现组成的药物制剂，当制剂用于口服施用时这是特别有益的。
对如此获得的晶形IV的药理研究已经证实它在中枢神经***和微循环中具有重要活性，这使得阿戈美拉汀的晶形IV被确立可用于治疗下列病症：紧张、睡眠紊乱、焦虑、严重抑郁症、季节性情感障碍、心血管疾病、消化***疾病、由时差导致的失眠和疲劳、精神***症、恐慌发作、忧郁症、食欲紊乱、肥胖症、失眠、疼痛、精神紊乱、癫痫、糖尿病、帕金森病、老年性痴呆、与正常或病理性老化有关的各种紊乱、偏头痛、记忆丧失、阿尔茨海默病以及脑循环紊乱。在另一个活性领域，表明阿戈美拉汀的晶形IV可用于治疗性功能障碍，具有***抑制和免疫调节的性质，并且可用于治疗癌症。
阿戈美拉汀的晶形IV优选用于治疗严重抑郁症、季节性情感障碍、睡眠紊乱、心血管疾病、由时差导致的失眠和疲劳、食欲紊乱和肥胖症。
本发明还涉及包含作为活性成分的阿戈美拉汀的晶形IV以及一种或多种适宜的惰性无毒赋形剂的药物组合物。在本发明的药物组合物中，可以提及的更特别是适于口服、胃肠道外(静脉内或皮下)或经鼻施用的那些，例如片剂或糖衣丸、颗粒剂、舌下片、明胶胶囊、锭剂、栓剂、乳膏剂、软膏剂、皮肤凝胶、可注射制剂、可饮用混悬剂和可崩解糊剂。
根据紊乱的性质和严重性、施用途径以及患者的年龄及体重调节有用剂量。剂量在每天0.1mg至1g之间变化，一次或多次施用。
具体实施方式
下列的实施例说明本发明，但不以任何方式限制本发明。
实施例1：N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺的晶形IV
于110℃加热100g N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺直至完全熔化，然后在50和70℃之间迅速冷却，并在70℃维持5小时直至结晶。所得晶形IV以下列的粉末X射线衍射图表征，使用西门子D5005衍射计(铜对阴极)进行测定，以晶面间距d、布拉格2θ角、强度和相对强度(以最强射线的百分数表示)表示：
  2θ角(°)实测值   d(_)实测值   强度(％)
  5.0410.1610.5115.2216.7517.4118.0318.8120.4821.6123.2724.0424.2724.7725.5727.0627.95   17.5248.7038.4095.8185.2885.0894.9154.7144.3334.1103.8193.6993.6653.5913.4813.2923.190   86892839601007137161126422413611
实施例2：药物组合物
制备1000片片剂的处方，每片含有25mg剂量：
实施例1的化合物……………………………………………25g
乳糖一水合物…………………………………………………62g
硬脂酸镁………………………………………………………1.3g
玉米淀粉………………………………………………………26g
麦芽糖糊精合剂………………………………………………9g
无水胶体二氧化硅……………………………………………0.3g
A型淀粉羟乙酸钠……………………………………………4g
硬脂酸…………………………………………………………2.6g
实施例3：药物组合物
制备1000片片剂的处方，每片含有25mg剂量：
实施例1的化合物……………………………………………25g
乳糖一水合物…………………………………………………62g
硬脂酸镁………………………………………………………1.3g
聚维酮…………………………………………………………9g
无水胶体二氧化硅……………………………………………0.3g
羧甲基纤维素钠………………………………………………30g
硬脂酸…………………………………………………………2.6g。

Claims (5)

1.式(I)的阿戈美拉汀的晶形IV：
以下列的粉末X射线衍射图表征，使用衍射计(铜对阴极)进行测定，以晶面间距d、布拉格2θ角、强度和相对强度(以最强射线的百分数表示)表示：   2θ角(°)实测值   d(_)实测值   强度(％)   5.0410.1610.5115.2216.7517.4118.0318.8120.4821.6123.2724.0424.2724.7725.5727.0627.95   17.5248.7038.4095.8185.2885.0894.9154.7144.3334.1103.8193.6993.6653.5913.4813.2923.190   86892839601007137161126422413611
2.权利要求1的式(I)化合物的晶形IV的制备方法，其特征在于，在110℃加热阿戈美拉汀直至完全熔化，然后在50和70℃之间迅速冷却，并在70℃维持约5小时直至结晶。
3.药物组合物，包含作为活性成分的权利要求1的阿戈美拉汀的晶形IV以及一种或多种可药用的惰性无毒载体。
4.权利要求3的药物组合物，用于制造治疗褪黑激素能紊乱的药物。
5.权利要求3的药物组合物，用于制造治疗下列病症的药物：睡眠紊乱、紧张、焦虑、季节性情感障碍或严重抑郁症、心血管疾病、消化***疾病、由时差导致的失眠和疲劳、精神***症、恐慌发作、忧郁症、食欲紊乱、肥胖症、失眠、精神紊乱、癫痫、糖尿病、帕金森病、老年性痴呆、与正常或病理性老化有关的各种紊乱、偏头痛、记忆丧失、阿尔茨海默病、脑循环紊乱，性功能障碍，用作***抑制剂和免疫调节剂，以及癌症。
CNB2006101083948A 2005-08-03 2006-08-03 阿戈美拉汀的新晶形ⅳ、它的制备方法和包含它的药物组合物 Expired - Fee Related CN100445264C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0508277A FR2889522B1 (fr) 2005-08-03 2005-08-03 Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR0508277 2005-08-03

Publications (2)

Publication Number Publication Date
CN1907957A true CN1907957A (zh) 2007-02-07
CN100445264C CN100445264C (zh) 2008-12-24

Family

ID=36589248

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2006101083948A Expired - Fee Related CN100445264C (zh) 2005-08-03 2006-08-03 阿戈美拉汀的新晶形ⅳ、它的制备方法和包含它的药物组合物

Country Status (25)

Country Link
EP (2) EP1752444A1 (zh)
JP (1) JP4580371B2 (zh)
CN (1) CN100445264C (zh)
AR (1) AR057714A1 (zh)
AU (1) AU2006203340B2 (zh)
BR (1) BRPI0603043A (zh)
CA (1) CA2555119A1 (zh)
CO (1) CO5780132A1 (zh)
EA (1) EA010867B1 (zh)
FR (1) FR2889522B1 (zh)
GE (1) GEP20094577B (zh)
GT (1) GT200600345A (zh)
HK (1) HK1098129A1 (zh)
MA (1) MA28450B1 (zh)
MX (1) MXPA06008693A (zh)
MY (1) MY141306A (zh)
NO (1) NO20063518L (zh)
NZ (1) NZ548863A (zh)
PE (1) PE20070242A1 (zh)
SA (1) SA06270254B1 (zh)
SG (1) SG130111A1 (zh)
TW (1) TWI327564B (zh)
UA (1) UA83718C2 (zh)
WO (1) WO2007015002A2 (zh)
ZA (1) ZA200606455B (zh)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101870662A (zh) * 2010-05-21 2010-10-27 中山大学 结晶型阿戈美拉汀溶剂化物及其制备方法
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN102001959A (zh) * 2009-09-01 2011-04-06 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
WO2011050742A1 (zh) * 2009-10-29 2011-05-05 重庆医药工业研究院有限责任公司 阿戈美拉汀的新晶型及其制备方法
CN101781226B (zh) * 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN101429134B (zh) * 2007-11-09 2012-05-23 瑟维尔实验室 阿戈美拉汀的晶形vi、它的制备方法和包含它的药物组合物
CN102503886A (zh) * 2011-10-11 2012-06-20 中山大学 阿戈美拉汀-异烟碱共晶及其组合物和制备方法
CN102643208A (zh) * 2012-04-14 2012-08-22 中山大学 一种阿戈美拉汀ⅰ晶型的制备方法
WO2012126385A1 (zh) * 2011-03-23 2012-09-27 上海医药工业研究院 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
CN101643432B (zh) * 2008-08-05 2012-12-12 瑟维尔实验室 获得v晶形阿戈美拉汀的新方法
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
MD4484C1 (ro) * 2011-03-23 2017-12-31 Hanghai Institute Of Pharmaceutical Industry Forma cristalină VIII a agomelatinei, procedeu de preparare, utilizarea acesteia şi compoziţie farmaceutică care o conţine

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2580183B1 (en) 2010-06-10 2014-07-23 Gador S.A. New process for the preparation of n-[2-(7-methoxy-1-naphthyl)-ethyl]acetamide
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2771312B1 (en) 2011-11-30 2017-05-31 ratiopharm GmbH Agomelatine-urea complex and crystalline forms thereof
CZ2012108A3 (en) 2012-02-15 2013-02-27 Zentiva Ks A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine
WO2014096373A1 (en) 2012-12-21 2014-06-26 Laboratorios Lesvi, S. L. Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof
FR3001894A1 (fr) 2013-02-08 2014-08-15 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
HUE036989T2 (hu) 2013-06-06 2018-08-28 Zentiva Ks Agomelatin készítmény, amely agomelatint ko-kristály formájában tartalmaz
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
CZ2013621A3 (cs) 2013-08-13 2015-02-25 Zentiva, K.S. Termodynamicky stabilní tuhý roztok agomelatinu pro použití ve farmaceutické formulaci
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine
ES2959460T3 (es) 2015-03-31 2024-02-26 Fis Fabbrica Italiana Sintetici Spa Forma sólida de agomelatina
EP3466413A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Pharmaceutical composition containing agomelatine and process for the preparation thereof
EP3466923A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Process for the preparation of agomelatine in crystalline form

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2866336B1 (fr) * 2004-02-13 2006-03-24 Servier Lab Nouveau procede de synthese du (7-methoxy-3,4-dihydro-1-naphtalenyl) acetonitrile et application a la synthese de l'agomelatine
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101429134B (zh) * 2007-11-09 2012-05-23 瑟维尔实验室 阿戈美拉汀的晶形vi、它的制备方法和包含它的药物组合物
CN101643432B (zh) * 2008-08-05 2012-12-12 瑟维尔实验室 获得v晶形阿戈美拉汀的新方法
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN102001959B (zh) * 2009-09-01 2014-07-02 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
CN102001959A (zh) * 2009-09-01 2011-04-06 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
CN102050755A (zh) * 2009-10-29 2011-05-11 重庆医药工业研究院有限责任公司 阿戈美拉汀的新晶型及其制备方法
CN102050755B (zh) * 2009-10-29 2014-11-05 重庆医药工业研究院有限责任公司 阿戈美拉汀的晶型及其制备方法
WO2011050742A1 (zh) * 2009-10-29 2011-05-05 重庆医药工业研究院有限责任公司 阿戈美拉汀的新晶型及其制备方法
US9029420B2 (en) 2009-12-23 2015-05-12 Tianjin Taipu Pharmaceutical Science & Technology Development Co., Ltd. Agomelatine and pharmaceutical compositions thereof
CN101781226B (zh) * 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN101870662B (zh) * 2010-05-21 2013-03-20 中山大学 结晶型阿戈美拉汀溶剂化物及其制备方法
CN101870662A (zh) * 2010-05-21 2010-10-27 中山大学 结晶型阿戈美拉汀溶剂化物及其制备方法
WO2012126385A1 (zh) * 2011-03-23 2012-09-27 上海医药工业研究院 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
EA023297B1 (ru) * 2011-03-23 2016-05-31 Шанхай Инститьют Оф Фармасьютикл Индастри Кристаллическая форма vii агомелатина, способ ее получения, применение и содержащая ее фармацевтическая композиция
MD4391C1 (ro) * 2011-03-23 2016-08-31 Hanghai Institute Of Pharmaceutical Industry Formă cristalină nouă VII a agomelatinei, procedeu de preparare şi utilizarea acesteia, şi compoziţie farmaceutică care o conţine
US9527803B2 (en) 2011-03-23 2016-12-27 Les Laboratoires Servier Crystal form VII of agomelatine, preparation method and use thereof and pharmaceutical composition containing same
MD4484C1 (ro) * 2011-03-23 2017-12-31 Hanghai Institute Of Pharmaceutical Industry Forma cristalină VIII a agomelatinei, procedeu de preparare, utilizarea acesteia şi compoziţie farmaceutică care o conţine
CN102503886B (zh) * 2011-10-11 2013-09-11 中山大学 阿戈美拉汀-异烟碱共晶及其组合物和制备方法
CN102503886A (zh) * 2011-10-11 2012-06-20 中山大学 阿戈美拉汀-异烟碱共晶及其组合物和制备方法
CN102643208B (zh) * 2012-04-14 2013-11-06 中山大学 一种阿戈美拉汀ⅰ晶型的制备方法
CN102643208A (zh) * 2012-04-14 2012-08-22 中山大学 一种阿戈美拉汀ⅰ晶型的制备方法

Also Published As

Publication number Publication date
NO20063518L (no) 2007-02-05
EP2008994A1 (fr) 2008-12-31
FR2889522B1 (fr) 2007-12-28
MY141306A (en) 2010-04-16
PE20070242A1 (es) 2007-05-06
AU2006203340A1 (en) 2007-02-22
JP4580371B2 (ja) 2010-11-10
AR057714A1 (es) 2007-12-12
WO2007015002A3 (fr) 2007-04-12
HK1098129A1 (en) 2007-07-13
GT200600345A (es) 2007-03-28
SA06270254B1 (ar) 2010-08-02
JP2007051141A (ja) 2007-03-01
NZ548863A (en) 2008-03-28
SG130111A1 (en) 2007-03-20
WO2007015002A2 (fr) 2007-02-08
CO5780132A1 (es) 2007-07-31
UA83718C2 (ru) 2008-08-11
CN100445264C (zh) 2008-12-24
FR2889522A1 (fr) 2007-02-09
EP1752444A1 (fr) 2007-02-14
BRPI0603043A (pt) 2007-03-20
EA010867B1 (ru) 2008-12-30
TW200736198A (en) 2007-10-01
EA200601271A1 (ru) 2007-02-27
GEP20094577B (en) 2009-01-12
MXPA06008693A (es) 2007-02-02
AU2006203340B2 (en) 2012-07-19
ZA200606455B (en) 2007-12-27
CA2555119A1 (fr) 2007-02-03
TWI327564B (en) 2010-07-21
MA28450B1 (fr) 2007-03-01

Similar Documents

Publication Publication Date Title
CN1907957A (zh) 阿戈美拉汀的新晶形ⅳ、它的制备方法和包含它的药物组合物
CN1907959A (zh) 阿戈美拉汀的新晶形ⅲ、它的制备方法和包含它的药物组合物
CN100448843C (zh) 阿戈美拉汀的新晶形ⅴ、它的制备方法和包含它的药物组合物
US7358395B2 (en) Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US8067639B2 (en) Crystalline form VI of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7939566B2 (en) Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7910625B2 (en) Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US8710101B2 (en) Co-crystals of agomelatine, a process for there preparation and pharmaceutical compositions containing them
KR100904116B1 (ko) 아고멜라틴의 ⅴ 결정형, 이의 제조 방법 및 이를 함유하는 약제 조성물
KR20070017020A (ko) 아고멜라틴의 결정질 형태 ⅳ, 이의 제조 방법 및 이를함유하는 약제 조성물
KR20070017019A (ko) 아고멜라틴의 결정질 형태 ⅲ, 이의 제조 방법 및 이를함유하는 약제 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1098129

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1098129

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081224

Termination date: 20210803